ASSET PURCHASE AGREEMENT by and among BLACKBIRD BIOFINANCE, LLC, as Seller, DR. SCOTT ANTONIA and SAM SHRIVASTAVA as Principals, CELLULAR BIOMEDICINE GROUP, INC. as Parent, CELLULAR BIOMEDICINE GROUP VAX, INC. as Buyer Dated as of June 8, 2015Asset Purchase Agreement • July 2nd, 2015 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of June 8, 2015, by and among Blackbird BioFinance, LLC, a Ohio limited liability company (“Seller”), Dr. Scott Antonia (“Antonia”), Sam Shrivastava (“Shrivastava” and together with Antonia, the “Principals”), Cellular Biomedicine Group, Inc., a Delaware corporation (“Parent”), and Cellular Biomedicine Group Vax, Inc., a California corporation and a wholly-owned subsidiary of Parent (“Buyer”).
Confidential Treatment Requested by Cellular Biomedicine Group, Inc IRS Employer Identification No. 86-1032927 Confidential treatment requested with respect to certain portions hereof denoted with “[***]” AMENDED AND RESTATED STANDARD EXCLUSIVE...Standard Exclusive License Agreement • July 2nd, 2015 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • Florida
This Amended and Restated Agreement (“Agreement”) is made effective June 3, 2015 (the “Effective Date”) by and between the University of South Florida Research Foundation, Inc. (hereinafter called “ Licensor”), a nonstock, nonprofit Florida corporation, under Chapter 617 Florida Statutes, and a direct support organization of the University of South Florida (“University”) pursuant to section 1004.28 Florida Statutes, and Blackbird BioFinance, LLC, an Ohio limited liability company having its principal office at 4500 Hyacinth Drive, Mason, Ohio 45040 (hereinafter called “Licensee”). Licensor and Licensee are at times referred to in this Agreement as “the parties.”
ASSIGNMENT AND ASSUMPTION OF LICENSE AGREEMENTAssignment and Assumption of License Agreement • July 2nd, 2015 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances)
This Assignment and Assumption of License Agreement (this “Assignment”) is made as of the 26th day of June, 2015, by and between Blackbird BioFinance, LLC, an Ohio limited liability company (“Assignor”), and Cellular Biomedicine Group Vax, Inc., a California corporation (“Assignee”). Capitalized terms used but not defined herein shall have the respective meanings assigned to them in the Purchase Agreement (as defined below).
